Strategic action for overcoming drug resistance in malaria – 2018

There is a need to develop safe and effective drugs that can be used to progress the malaria elimination agenda, and with a particular emphasis on pregnant women, infants and children. Current treatment of malaria is highly dependent on artemisinin-based combination therapies (ACT), but emerging resistance has highlighted the need to develop a broader portfolio of antimalarial drugs, including new or repurposed non-ACT drugs for chemoprevention and treatment as well as long-acting products with transmission-blocking potential.

This Call for proposals aimed to support one large-scale strategic action (clinical research activities) as part of a bigger portfolio of clinical trials with the capacity to develop new and diverse antimalarial drugs against Plasmodium falciparum and/or Plasmodium vivax, including combination therapies that may be used for treatment or chemoprevention of malaria in sub-Saharan Africa.

Call identifier: RIA2018SD

Portfolio approach to developing the next generation of malaria treatments for Africa

Medicines for Malaria Venture (MMV) Cointrin, Switzerland, with partners in Burkina Faso, Gabon, Germany, Mozambique, Spain, Switzerland, and Uganda.
Project coordinator: Dr Tim Wells (MMV)
Starting date: 01 January 2020
Duration: 60 months
EDCTP grant amount: EUR 21,990,938
Grant agreement: RIA2018SD-2306